Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.

The synthesis and biological evaluation of potent hydroxamate-based dual HDAC1/6 inhibitors with modest HDAC6 preference and a novel alkoxyurea connecting unit linker region are described. The biological studies included the evaluation of antiproliferative effects and HDAC inhibitory activity in the human ovarian cancer cell line A2780, the human squamous carcinoma cell line Cal27, and their cisplatin resistant sublines A2780CisR and Cal27CisR. The three most potent compounds 1g-i showed IC50 values in the low μM and sub-μM range. 1g-i revealed low nM IC50 values for HDAC6 with up to 15-fold preference over HDAC1, >3500-fold selectivity over HDAC4, and >100-fold selectivity over HDAC8. Furthermore, their ability to enhance cisplatin sensitivity was analyzed in Cal27 and Cal27CisR cells. Notably, a 48 h preincubation of 1g-i significantly enhanced the antiproliferative effects of cisplatin in Cal27 and Cal27CisR. 1g-i interacted synergistically with cisplatin. These effects were more pronounced for the cisplatin resistant subline Cal27CisR.

[1]  Bruce J. Melancon,et al.  Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. , 2016, Nature chemical biology.

[2]  Giuseppe Marco Randazzo,et al.  A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors , 2016, Scientific Reports.

[3]  K. Smalley,et al.  Essential role of HDAC6 in the regulation of PD‐L1 in melanoma , 2016 .

[4]  D. Christianson,et al.  Histone deacetylase 6 structure and molecular basis of catalysis and inhibition , 2016, Nature chemical biology.

[5]  O. Witt,et al.  Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors. , 2016, Journal of medicinal chemistry.

[6]  H. Gohlke,et al.  Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors. , 2016, Chemical communications.

[7]  P. Proksch,et al.  Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780 , 2016, Journal of Cancer.

[8]  A. Mazar,et al.  Identification of HDAC6‐Selective Inhibitors of Low Cancer Cell Cytotoxicity , 2016, ChemMedChem.

[9]  Z. Ning,et al.  Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Tae Won Kim,et al.  First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies , 2015, Investigational New Drugs.

[11]  G. Rastelli,et al.  Histone deacetylases: structural determinants of inhibitor selectivity. , 2015, Drug discovery today.

[12]  Karly P Garnock-jones.  Panobinostat: First Global Approval , 2015, Drugs.

[13]  O. Wiest,et al.  Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8. , 2015, Biochemistry.

[14]  J. Berenson,et al.  The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma , 2014, Therapeutic advances in hematology.

[15]  R. Johnstone,et al.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2014, Nature Reviews Drug Discovery.

[16]  E. Winzeler,et al.  Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. , 2014, European journal of medicinal chemistry.

[17]  G. McFadden,et al.  Lysine Acetylation in Sexual Stage Malaria Parasites Is a Target for Antimalarial Small Molecules , 2014, Antimicrobial Agents and Chemotherapy.

[18]  E. Seto,et al.  Erasers of histone acetylation: the histone deacetylase enzymes. , 2014, Cold Spring Harbor perspectives in biology.

[19]  F. Hansen,et al.  Synthesis, Antimalarial Properties, and SAR Studies of Alkoxyurea‐Based HDAC Inhibitors , 2014, ChemMedChem.

[20]  R. Bürli,et al.  Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. , 2013, Journal of medicinal chemistry.

[21]  Ju-Hee Lee,et al.  Development of a histone deacetylase 6 inhibitor and its biological effects , 2013, Proceedings of the National Academy of Sciences.

[22]  W. Sippl,et al.  Structural Basis for the Inhibition of Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the Blood Fluke Schistosoma mansoni , 2013, PLoS pathogens.

[23]  C. Robinson,et al.  Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates , 2013, Molecular cell.

[24]  R. A. Reid,et al.  Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. , 2013, Nature chemical biology.

[25]  D. E. Olson,et al.  Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif. , 2013, Journal of medicinal chemistry.

[26]  S. Lewin,et al.  Comparison of HDAC inhibitors in clinical development , 2013, Human vaccines & immunotherapeutics.

[27]  H. Gohlke,et al.  Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. , 2013, Journal of medicinal chemistry.

[28]  A. Kozikowski,et al.  Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. , 2012, Journal of medicinal chemistry.

[29]  F. Zunino,et al.  Development and therapeutic impact of HDAC6-selective inhibitors. , 2012, Biochemical pharmacology.

[30]  V. Adam,et al.  The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. , 2012, Current medicinal chemistry.

[31]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[32]  S. Chan,et al.  Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells. , 2012, International journal of oncology.

[33]  M. Lübbert,et al.  The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO , 2011, Oncogene.

[34]  M. Lübbert,et al.  Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy , 2010, Clinical Epigenetics.

[35]  F. Hansen,et al.  Convenient Synthesis of 5‐Substituted 2‐Amino[1,2,4]triazolo[1,5‐a][1,3,5]triazin‐7(6H)‐ones from N‐Triazolide Imidates and 1,2,4‐Triazole‐3,5‐diamine. , 2010 .

[36]  N. Meanwell,et al.  Synthesis of 3-Hydroxypyrimidine-2,4-diones. Addition of Anilines to Benzyloxy Isocyanate Synthons to Give N-Hydroxyureas , 2010 .

[37]  Kyle V. Butler,et al.  Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. , 2010, Journal of the American Chemical Society.

[38]  F. Hansen,et al.  Convenient Synthesis of 5-Substituted 2-Amino[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(6H)-ones from N-Triazolide Imidates and 1,2,4-Triazole-3,5-diamine , 2010 .

[39]  M. Rohmer,et al.  Isoprenoid biosynthesis via the methylerythritol phosphate pathway: structural variations around phosphonate anchor and spacer of fosmidomycin, a potent inhibitor of deoxyxylulose phosphate reductoisomerase. , 2010, The Journal of organic chemistry.

[40]  R. Johnstone,et al.  Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. , 2009, Future oncology.

[41]  C. Grunau,et al.  Schistosoma mansoni: developmental arrest of miracidia treated with histone deacetylase inhibitors. , 2009, Experimental parasitology.

[42]  B. Györffy,et al.  Acquired cisplatin resistance in the head–neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1 , 2008, International journal of cancer.

[43]  J. Minna,et al.  Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells* , 2008, Journal of Biological Chemistry.

[44]  N. Mills.  ChemDraw Ultra 10.0 CambridgeSoft, 100 CambridgePark Drive, Cambridge, MA 02140. www.cambridgesoft.com. Commercial Price: $1910 for download, $2150 for CD-ROM; Academic Price: $710 for download, $800 for CD-ROM. , 2006 .

[45]  M. Jung,et al.  In vitro assays for the determination of histone deacetylase activity. , 2005, Methods.

[46]  H. Gohlke,et al.  Improving binding mode predictions by docking into protein-specifically adapted potential fields. , 2005, Journal of medicinal chemistry.

[47]  P. Purushottamachar,et al.  A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. , 2005, Journal of medicinal chemistry.

[48]  F. Dequiedt,et al.  Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. , 2003, Analytical biochemistry.

[49]  G. Klebe,et al.  DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. , 2002, Journal of medicinal chemistry.

[50]  Gerhard Klebe,et al.  Docking into knowledge-based potential fields: a comparative evaluation of DrugScore. , 2002, Journal of medicinal chemistry.

[51]  M. Jung,et al.  A non-isotopic assay for histone deacetylase activity. , 1999, Nucleic acids research.

[52]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[53]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[54]  S. A. Ganai.  Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy. , 2016, Current topics in medicinal chemistry.

[55]  T. Senawong,et al.  Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines. , 2016, International journal of oncology.

[56]  H. Gohlke,et al.  Rational design and diversity-oriented synthesis of peptoid-based selective HDAC 6 inhibitors † , 2016 .

[57]  D. S,et al.  Essential role of HDAC6 in the regulation of PD‐L1 in melanoma , 2016, Molecular oncology.

[58]  Z. Ning,et al.  Results from amulticenter , open-label , pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma , 2015 .

[59]  J. Bradner,et al.  selective HDAC 6 inhibitor , ACY-1215 , in combination with bortezomib in Preclinical activity , pharmacodynamic and pharmacokinetic properties of a , 2012 .

[60]  T. Beckers,et al.  A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening. , 2008, Analytical biochemistry.

[61]  M. Carducci,et al.  Evaluation of the Pharmacodynamic Effects of MGCD 0103 from Preclinical Models to Human Using a Novel HDAC , 2008 .

[62]  D. Wegener,et al.  A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. , 2003, Chemistry & biology.

[63]  D. Goodsell,et al.  Automated docking to multiple target structures: Incorporation of protein mobility and structural water heterogeneity in AutoDock , 2002, Proteins.

[64]  Protein-Ligand Interactions,et al.  Knowledge-based Scoring Function to Predict , 2000 .